Delving into the Latest Updates on Stem cell-based therapy (SCM Lifescience/Steminent Biotherapeutics) with Synapse

Overview

Basic Info

Drug Type

Stem cell therapy

Synonyms-

Target-

Mechanism

Cell replacements

Therapeutic Areas

Immune System DiseasesCongenital DisordersDigestive System Disorders+ [2]

Active Indication

Chronic graft-versus-host diseaseDermatitis, AtopicPancreatitis

Inactive Indication

Cerebellar AtaxiaRespiratory Distress Syndrome, Adult

Originator Organization

SCM Lifescience Co., Ltd.

Active Organization

SCM Lifescience Co., Ltd.

Inactive Organization

Steminent Biotherapeutics, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Cancer-related deaths are still the most fearsome threaten to human health. It is necessary to develop an innovative and active strategy for the prophylactic immunization against tumorigenesis. Multiple lines of evidence have demonstrated that cancer stem cells (CSCs) are the initiating cells of tumor formation, as well as the source of local recurrence and distant metastases. Mesenchymal stem cells (MSCs), the adult pluripotent progenitors of multiple mesenchymal lineages, have an unusual tropism to preclinical tumor lesions. Both MSCs and CSCs or populations of tumor-initiating cells may also have similar reactogenicity or immunogenicity. Based on the information given above, a hypothesis is generated that MSCs may possess a potential of cellular vaccine for bio-prevention against tumorigenesis via eliciting cross-immunity and inducing active antibodies.

100 Deals associated with Stem cell-based therapy (SCM Lifescience/Steminent Biotherapeutics)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic graft-versus-host disease	Phase 2	KR	SCM Lifescience Co., Ltd.	30 Jan 2022
Dermatitis, Atopic	Phase 2	KR	SCM Lifescience Co., Ltd.	30 Jan 2022
Pancreatitis	Phase 2	KR	SCM Lifescience Co., Ltd.	30 Jan 2022
Respiratory Distress Syndrome, Adult	Phase 1	KR	SCM Lifescience Co., Ltd.	16 Nov 2021
Cerebellar Ataxia	Phase 1	KR	Steminent Biotherapeutics, Inc.	14 Mar 2020